Routine comprehensive geriatric assessment is associated with improved detection of cognitive disorders in older people with giant cell arteritis
- PMID: 40256905
- DOI: 10.1111/ajag.70020
Routine comprehensive geriatric assessment is associated with improved detection of cognitive disorders in older people with giant cell arteritis
Abstract
Objectives: Giant cell arteritis (GCA) carries an increased risk of stroke and blindness. International guidelines recommend older people receive routine comprehensive geriatric assessment (RCGA) during unplanned hospital admissions to improve health outcomes. This quality improvement study addressed the need for RCGA in older people with GCA at an Australian tertiary hospital. The aims of this study were to co-design, implement and evaluate a referral process for RCGA for hospitalised people 65 years or older with a new diagnosis of GCA and evaluate changes to the identification and management of falls and cognitive disorders (delirium, dementia and mild cognitive impairment).
Methods: Hospital stakeholders co-designed an RCGA referral pathway as a quality improvement change initiative. An observational cohort design measured implementation and outcomes. Consecutive patients aged 65 years or older with a new diagnosis of GCA were recruited for 15 months (n = 18), and outcomes were compared with a retrospective cohort of similar patients (n = 55). Descriptive summaries were compared between groups using non-parametric tests.
Results: Following implementation, all eligible patients received both RCGA and individualised interventions. Forty-four per cent of patients in the RCGA group were diagnosed with delirium, dementia or mild cognitive impairment compared to 18% in the usual care group (p = .03).
Conclusions: In this small population, implementation of an RCGA pathway was associated with increased detection of delirium, mild cognitive impairment and dementia, and allowed for implementation of individualised interventions.
Keywords: delirium; dementia; geriatric assessment; giant cell arteritis.
© 2025 AJA Inc.
References
REFERENCES
-
- Dunstan E, Lester SL, Rischmueller M, et al. Epidemiology of biopsy‐proven giant cell arteritis in South Australia. Intern Med J. 2014;44(1):32‐39. doi:10.1111/imj.12293
-
- Wilson J, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case‐control analysis. Semin Arthritis Rheum. 2017;46(6):819‐827.
-
- Proven A, Gabriel S, Orces C, O'Fallon W, Hunder G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703‐708.
-
- Sartori A, Vance D, Slater L, Crowe M. The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs. 2012;44(4):206‐217.
-
- Solans‐Laqué R, Bosch‐Gil J, Molina‐Catenario C, Ortega‐Aznar A, Alvarez‐Sabin J, Vilardell‐Tarres M. Stroke and multiinfarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore). 2008;87:335‐344.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
